Biogen Idec Inc. has applied to the Food and Drug Administration for approval to market a new treatment for hemophilia B, the Weston biotechnology company said Friday.

Hemophilia B is a rare inherited disease that keeps patients’ blood from clotting and can cause bleeding, joint damage, and life-threatening hemorrhages. Biogen Idec said it submitted its biologics license application to the FDA recently and expects a decision some time this year. It is the first product in a class of clotting therapies the company is developing.